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Abstract  
We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) 
mutations and voice. Sustained phonations (‘aaah’ sounds) were recorded from 7 
individuals with LRRK2-associated Parkinson’s disease (PD), 17 participants with idiopathic 
PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 
controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 
17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting 
carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in 
LRRK2-associated PD may be different than those in iPD. These preliminary results warrant 
longitudinal analyses and replication in larger cohorts.  
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Introduction  
Voice impairment may be one of the earliest motor indicators of idiopathic Parkinson’s 
disease (iPD) [1], and is typically characterized by breathiness, roughness, reduced loudness, 
and vocal tremor [1-4]. It is estimated that between 70 and 90% of people with PD (PWP) 
experience vocal impairment [2, 5, 6], and nearly one-third of PWP report voice-related 
problems as one of their main disease-related limitations [6].  
Past work has demonstrated that objective measures of vocal impairment can be used to 
distinguish participants with iPD from controls with a high accuracy (mean sensitivity and 
mean specificity > 90%) [7-15]. The extent of vocal dysfunction has also been shown to be 
associated with disease severity [3, 16, 17]. Moreover, for symptom monitoring, voice-
based measures have been used to accurately replicate both the motor and total Unified 
Parkinson’s Disease Rating Scale (UPDRS) assessment (within 2 points from the clinicians’ 
estimate) [18]. Recently, abnormalities in speech production have also been reported in 
participants with idiopathic rapid eye movement (REM) sleep behaviour disorder [19, 20]. 
These findings encourage further investigation of voice analysis as a reliable, non-invasive, 
and scalable tool that may also identify prodromal PD.  
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of 
genetically-determined PD [21]. The opportunity to intervene with disease-modifying 
therapy early in the neurodegenerative process makes identifying the prodromal state 
important. To investigate the presence of voice abnormalities in populations at increased 
risk to develop PD, in this study we analyse voice-based measures in multiplex families 
carrying a mutation in the gene for LRRK2. The goals of this pilot study were thus twofold. 
First, we aimed to determine if voice can be used to discriminate participants with LRRK2-
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associated PD from idiopathic PD. Second, we examined if there are any differences in voice 
between non-manifesting carriers of a LRRK2 mutation when compared to related non-
manifesting non-mutation carriers and unrelated healthy controls.  
Methods 
Study participants 
Probands with LRRK2 mutations were identified at Toronto Western Hospital and all 
available blood relatives were invited to participate. iPD patients and healthy individuals 
(devoid of any neurologic disease or family history of PD) were recruited at Toronto 
Western Hospital. iPD was defined as individuals with PD, according to clinical diagnosis by a 
movement disorder specialist, in the absence of a family history of the disease in a first or 
second-degree relative. Seven participants with LRRK2-PD (p.P.G2019S (5) or L1795F (2)), 17 
participants with iPD, 20 non-manifesting carriers of LRRK2 mutations (p.G2019S (18), 
L1795F (2)), 25 related non-manifesting non-carriers, and 26 healthy controls were 
recruited. The presence or absence of a LRRK2 mutation was evaluated in all participants as 
described previously [22]. In the non-manifesting carrier group, the likelihood of prodromal 
disease being present was determined [23]. The study was approved by the University 
Health Network Research Ethics Board and informed consent was obtained from all 
participants.   
 
Data acquisition 
We obtained two audio recordings of sustained vocal phonation from each participant 
during a study visit at the Toronto Western Hospital using a USB powered microphone 
(Logitech, model 980186-0403) positioned on a stable surface ~2 inches from the 
participant’s mouth. Recordings were collected using Audacity software (Version 2.0.3) in a 
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quiet room. Participants with iPD were evaluated in the ON medication state. Each 
participant was instructed to “Take a deep breath and then let out a single "aaah" sound for 
as long as you can.” Each recording was sampled at 44.1 kHz and stored as a de-identified 
digital audio file (.wav format).   
 
Data processing 
Identification of the longest usable segment of sustained phonation for each recording was 
performed manually. Recordings were discarded from the analysis if they were too noisy or 
if the phonation duration was shorter than two seconds. For each recording, we extracted 
292 summary measures (also referred to as features or dysphonia measures) that have been 
used for analysing voice, including in PD [10, 14, 18, 24]. Details regarding these features are 
provided in the Supplementary section.   
 
Statistical analysis 
We identified 3 pairwise comparisons of interest: (1) LRRK2-PD versus iPD, (2) Non-
manifesting carriers versus related non-manifesting non-carriers, and, (3) Non-manifesting 
carriers versus healthy controls. For each pairwise comparison, salient features were 
identified using the following 5 feature selection algorithms that help enhance the 
explanatory power of the analysis by removing redundant and less informative features [25-
29]. Each of the 5 feature selection algorithms provided a unique set of feature ranking. To 
obtain a single ranking of the most salient features to be used for group comparison, we 
used a majority voting scheme. Pairwise comparisons were performed using a highly 
nonlinear statistical machine learning algorithm (random forests), used to separate generic 
feature data into several different classes [30]. Discrimination accuracy was evaluated using 
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a 10-fold cross-validation (CV) scheme (with 100 repetitions for statistical confidence). This 
scheme helps assess generalizability of the discrimination results to similar, but previously 
unseen data, and has been used in previous studies on voice analysis in PD [10, 14, 18]. Data 
was balanced in each cross-validation repetition to eliminate differences in group sample 
size. The statistical significance level was set to p=0.05. Statistical analysis of the voice 
recordings was performed using the Matlab® software (version 2016b). Details regarding 
statistical analysis focussing on feature extraction, feature selection, and validation are 
provided in the Supplementary section. 
 
Results 
LRRK2-PD vs idiopathic PD 
On average, LRRK2-PD participants were older and had a longer disease duration compared 
to participants with iPD (Table 1). However, UPDRSIII (motor UPDRS) between the two 
groups was similar. Two recordings were collected from each participant, however, 3 LRRK2-
PD and 2 iPD voice recordings were discarded as they were too noisy for reliable 
computation of features. Accuracies to distinguish LRRK2 PD from iPD are reported in Table 
1 and were computed using the 10 most salient features. Including more features in the 
classifier (random forest) improved the discrimination accuracy only marginally 
(Supplementary Figure 2). In discriminating participants using 11 LRRK2-PD (n = 7 
individuals) and 32 iPD voice recordings (n = 17 individuals), the mean sensitivity was 95.4% 
(Standard Deviation (SD) 17.8%) and mean specificity was 89.6% (SD 26.5%). Results were 
very similar for males and females (Table 1); in discriminating recordings from female 
participants, the mean sensitivity was 99.4% (SD 7.1%) and mean specificity was 85.7% (SD 
34.1%), whereas for male participants, the mean sensitivity was 100% (SD 0%) and mean 
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specificity was 88.9% (SD 31.6%). Stratification of data based on sex resulted in too few 
recordings to adequately fit the random forest classifier, which reduces the reliability of 
analysis and inference, particularly for LRRK2-PD (n = 7). Statistically significant differences 
were observed between LRRK2-PD and iPD voice features (see Figure 1 (showing clear 
separation plotting 2 salient features) and Supplementary Figure 1). Details regarding the 
most salient features are provided (Supplementary Table 3). 
Accuracies were also computed using leave-one-subject-out (LOSO) CV [31]. Using LOSO 
CV, the mean sensitivity was 83.7% and mean specificity was 88.5% in discriminating LRRK2-
PD from iPD (see Supplementary Table 2).  
We performed additional analysis whereby non-manifesting LRRK2 carriers and 
individuals with LRRK2-associated PD were treated as belonging to the same clinical group. 
This resulted in a larger sample of LRRK2 carriers (n=27) which helped improve statistical 
power. The rationale of this analysis was to investigate if vocal deficits in LRRK2 carriers 
(both manifesting and non-manifesting) were different from iPD (for details, see 
Supplementary analysis).  
 
Non-manifesting carriers (NMC) versus Related Non-carriers (RNC) and Controls 
Participants from the three groups were of similar age (Table 1). NMC had a higher UPDRSIII 
score compared to both healthy controls and RNC. Statistical analyses were performed using 
39 NMC recordings (n = 20), 48 RNC recordings (n = 25), and 47 control recordings (n = 26). 
In discriminating NMC from RNC, the mean sensitivity was 74.9% (SD 24.0%) and mean 
specificity was 78.0% (SD 23.3%). Moreover, in discriminating NMC from unrelated healthy 
controls, the mean sensitivity was 75.7% (SD 24.3%) and mean specificity was 81.8% (SD 
20.4%). Scatterplots of the most salient features for these pairwise comparisons do not 
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allow readily visible identification of this discrimination (Figure 1). Compared to LRRK2-PD 
and iPD features, therefore, the voice features for NMC, RNC, and healthy controls were 
much less discriminatory. 
 
Discussion 
Our preliminary analyses found statistically significant differences between LRRK2-PD and 
iPD (p<0.01) in features extracted from sustained phonations (Figure 1 and Supplementary 
Figure 1). The differences in the features were less pronounced when non-manifesting 
carriers were compared with related non-carriers and healthy controls. Thus, voice could 
potentially be used as a non-invasive and inexpensive biomarker for identifying a LRRK2 
mutation in PD participants, but seems to be less promising as a potential marker for the 
prodromal phase of LRRK2-PD.  
A limitation of this study is the small sample size, particularly for participants with LRRK2-
PD. We investigated and verified that unique participant identity was not a confounder (see 
Supplementary analysis) [32]. LRRK2-PD participants were older than iPD participants and 
we cannot rule out the effect of presbyphonia as a potential confound [33]. However, 
including age as a covariate in the classification model did not result in improved 
classification accuracy, indicating that if presbyphonia exists in this cohort its effects may be 
negligible. Moreover, the predictive accuracy obtained using machine learning algorithms 
and multiple features do not lead to ready etiologically-relevant explanations for why voice 
impairment might be discriminatory in this context [34]. This hinders our ability to make 
inferences regarding underlying pathophysiological changes associated with an impaired 
voice in PD.  
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We find that statistical analysis of sustained phonations help discriminate LRRK2-PD and 
iPD. The findings of this study add to the growing evidence supporting clinical and 
pathological differences between LRRK2-PD and iPD, whereby differences in both motor and 
nonmotor features (including heart rate variability, tremor, gait, olfactory identification) 
have been previously reported [35-40]. To the best of our knowledge, this is the first proof-
of-concept study that investigates potential vocal deficits in manifesting and non-
manifesting LRRK2-carriers. These results warrant further investigation into the potential of 
using voice for the delineation of PD subtypes in larger cohorts.   
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TABLE 1.  Descriptive statistics by group (A), comparison of clinical and demographic 
characteristics (B), and discrimination accuracy for pairwise comparisons (C).  
 
A. Descriptive statistics by 
group 
n Age 
Mean  (SD) 
% 
female 
UPDRSIII 
Mean  (SD) 
Disease duration 
Mean (SD) 
LRRK2-PD 7 72.3 
(13.1) 
57% 21.9 
(18.7) 
10.3 
(11.8) 
Idiopathic PD 
(iPD) 
17 63.4 
(8.7) 
53% 22.8 
(10) 
5.4 
(5.8) 
Non-manifesting carriers 
(NMC) 
20 58.3 
(14.5) 
45% 4.1 
(3.7) 
n.a. 
Related non-carriers 
(RNC) 
25 53.7 
(16.3) 
64% 2.7 
(4.2) 
n.a. 
Healthy control 
(unrelated) 
26 54.0 
(16.1) 
69% 1.6 
(1.8) 
n.a. 
 
 
B. Comparing descriptive 
statistics (p values) 
 
 Age  UPDRSIII Disease duration 
LRRK2-PD vs iPD  0.06  0.55 0.21 
NMC vs RNC  0.33  0.04 - 
NMC vs Healthy  0.36  0.01 - 
 
 
C. Discrimination accuracy 
Sensitivity (%) 
Mean (SD) 
Specificity (%) 
Mean  (SD) 
   
LRRK2-PD vs iPD (ALL) 95.4% (17.8%) 89.6% (26.5%) 
LRRK2-PD vs iPD (FEMALE) 99.4% (7.1%) 85.7% (34.1%) 
LRRK2-PD vs iPD (MALE) 100.0% (0%) 88.9% (31.6%) 
   
NMC vs RNC (ALL) 74.9% (24.0%) 78.0% (23.3%) 
NMC vs RNC (FEMALE) 80.2% (32.1%) 71.7% (36.5%) 
NMC vs RNC (MALE) 90.6% (22.6%) 85.1% (28.9%) 
   
NMC vs Healthy (ALL) 75.7% (24.3%) 81.8% (20.4%) 
NMC vs Healthy (FEMALE) 87.3% (26.3%) 84.6% (28.6%) 
NMC vs Healthy (MALE) 75.4% (34.8%) 82.1% (31.0%) 
 
The table is presented in three different sections (A-C). Section A presents descriptive statistics for the five clinical groups 
(1. LRRK2-PD, 2. iPD, 3. NMC, 4. RNC, and, 5. Healthy controls). Section B compares the descriptive statistics. Age was 
analyzed using an unpaired t-test, whereas disease duration and UPDRSIII total were compared using Mann–Whitney U 
test. p values <0.05 are highlighted in the bold italic text. Section C presents the out-of-sample discrimination accuracy for 
the three priority pairwise comparisons (1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs Healthy) using a 10-fold cross-
validation (CV) scheme (with 100 repetitions), employing only the 10 most salient voice features. The scheme involved 
repetitive splitting of the data into a training set (90% of the total observations) and a validation set (remaining 10% of the 
observations). The mean sensitivity and mean specificity across different CV repetitions are presented (along with standard 
deviation in brackets). The data was balanced to account for differences in group sample size. Accuracies were computed 
using all recordings, and separately for subgroup analysis using data stratified by sex. Abbreviations used: iPD, idiopathic 
Parkinson’s disease; LRRK2-PD, LRRK2-associated Parkinson’s disease; NMC, non-manifesting carriers; RNC, related non-
carriers; SD, standard deviation; UPDRSIII, Movement Disorders Society Unified Parkinson’s Disease Rating Scale part 3; 
n.a., not applicable.  
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FIGURE 1 TITLE. Scatterplots and boxplots of salient features for the three pairwise 
comparisons: LRRK2-PD versus idiopathic PD (iPD) (Panels A and B), non-manifesting carriers 
(NMC) versus related non-carriers (RNC) (Panels C and D), and NMC versus healthy controls 
(Panels E and F). 
 
Panel A shows two highly discriminatory features that help differentiate LRRK2-PD from iPD. In Panel A, we 
plot Entropy (entropy computed after wavelet decomposition, quantifies extent of randomness in a signal) and 
Glottis to Noise Excitation (GNE, degree of signal strength versus noise resulting from incomplete vocal fold 
closure), both features were significantly different (p<0.001, denoted by ***) (Panel B). Panel C plots two 
salient features that help discriminate NMC from RNC. In Panel C, we plot Harmonic to Noise Ratio (HNR, 
signal to noise ratio) and median shimmer (roughness in voice). HNR between the two groups was significantly 
different (p<0.01, denoted by **), whereas shimmer between NMC and RNC was similar (p>0.05) (Panel D), 
which indicates that the two cohorts are less different (as reflected in the discrimination accuracies reported in 
Table 1). Panel E shows two salient features that discriminate NMC from healthy controls. In Panel E, we plot 
Mel Frequency Cepstral Coefficient (MFCC, quantifies vocal fold dynamics depending on properties of the 
articulators) and median shimmer. Panel F shows that MFCC and shimmer were significantly different between 
the two groups. Salient features were identified separately for each pairwise comparison, using five different 
feature selection algorithms. The above plots were generated using all usable voice recordings. p values 
reported above were computed using the nonparametric two-sided Kolmogorov-Smirnov (KS) test. 
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Supplementary material for ‘Investigating Voice as a Biomarker for leucine-
rich repeat kinase 2-Associated Parkinson’s Disease’ 
 
Supplementary Analysis 
Feature extraction 
For each recording, we extracted 292 summary measures (also referred to as features). 
These features can broadly be characterized as: (1) Descriptive features: statistical 
characteristics of voice. (2) Vocal fold vibration-based features: variation in speech 
frequency and amplitude. (3) Cepstral coefficients: subtle changes in the placement of the 
articulators (mouth, tongue, teeth and lips). (4) Aeroacoustics-based features: degree of 
turbulent noise in speech due to incomplete vocal fold closure. (5) Wavelet features: 
extended time-frequency domain properties. Details regarding these feature categories are 
provided in Supplementary Table 1.   
 
Feature selection 
For each pairwise comparison, salient features were identified using the following 5 feature 
selection algorithms that help enhance the explanatory power of the analysis by removing 
redundant and less informative features: (1) Minimum redundancy maximum 
relevance (mRMR) [27], (2) Gram-Schmidt orthogonalization (GSO) [25], (3) RELIEF [26], (4) 
Local learning-based feature selection (LLBFS) [28], and (5) Least absolute shrinkage and 
selection operator (LASSO) [29].  
 
Validation  
In this study, we used two model validation schemes: (1) 10-fold cross-validation: this 
scheme involves randomly splitting the data into two non-overlapping parts, the first part of 
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the data (comprising 90% of the recordings) are used to train the model (i.e., learn the 
underlying differences in patterns of voice-based features for each pairwise comparison), 
while the remaining 10% of the recordings are used for validation (i.e., evaluate the 
accuracy of model predictions). This process of randomized selection of training and 
validation sets was repeated multiple times, and the discrimination accuracies (quantified 
using sensitivity and specificity) were calculated on each repetition. (2) Leave-one-subject-
out: this scheme involves splitting the data such that all recordings from only one 
participant are used for model validation, while all remaining recordings are used for 
training. This process is repeated multiple times. Note that for both schemes, the accuracy 
of model predictions are computed using only the validation set. Basically, the model is 
blinded to the validation set during the training process, which helps gauge generalizability 
of the model to previously unseen similar datasets. 
In this study, we analysed all available/suitable voice recordings leading to a mismatch in 
the five group sizes (Table 1). Whilst there are fewer LRRK2-associated PD participants 
compared to iPD, it should be noted that we used a ‘balanced cross-validation scheme’ that 
results in an equal number of samples across different classes for each pairwise comparison. 
This scheme helps mitigate the issues associated with imbalanced datasets/differences in 
group sizes. 
 
LRRP2-PD vs idiopathic PD (excluding 1 LRRK2-PD participant) 
LRRP2-PD participants had longer mean disease duration (n = 7, mean = 10.3 years, SD = 
11.8 years) compared to participants with iPD (n = 17, mean = 5.4 years, SD = 5.8 years). 
One LRRK2-PD participant had a disease duration of 36 years, and without this participant, 
the mean disease duration for the remaining 6 LRRK2-PD participants was 6 years (SD = 3.7 
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years), which is similar to the mean disease duration for iPD participants (5.4 years). 
Statistical analyses were thus performed separately by excluding this LRRK2-PD participant 
(disease duration 36 years, female, age 85 years, one voice recording available). The 
rationale for this analysis was to investigate disease duration as a potential confounding 
factor in discriminating LRRK2-PD versus iPD. Using 10 voice recordings collected from the 
remaining 6 LRRK2-PD participants, we recomputed the accuracy in discriminating LRRK2-PD 
versus iPD.  
Using only the 10 top-ranked features for this pairwise comparison, the mean sensitivity 
and mean specificity was 97.0% (SD 15.5%) and 87.2% (SD 31.1%) in discriminating LRRK2-
PD from iPD using all recordings, 99.0% (SD 10.0%) and 82.4% (SD 38.1%) in discriminating 
LRRK2-PD from iPD using only female recordings, and 100% (SD 0%) and 88.9% (SD 31.6%) in 
discriminating LRRK2-PD from iPD using only male recordings. These accuracies were 
obtained using 10-fold cross-validation. Note that the excluded LRRK2-PD recording was 
collected from a female participant; hence the accuracy in discriminating LRRK2-PD versus 
iPD using only male recordings was the same as those reported in Table 1. For leave-one-
subject-out cross-validation, mean sensitivity and mean specificity were 88.5% (SD 7.8%) 
and 81.3% (SD 12.3%) respectively, in discriminating LRRK2-PD from iPD using all recordings. 
The sample size was too small to draw any reliable inference based on discrimination 
accuracies for subgroup analysis stratified by sex. These sensitivity and specificity values 
(obtained using recordings from n = 6 LRRK2-PD participants) are in close agreement with 
the discrimination accuracies obtained using all available recordings for LRRK2-PD (n = 7), as 
reported in Table 1 and Supplementary Table 2. Encouragingly, for all pairwise comparisons 
reported above, the sensitivity and specificity results differed statistically significantly from 
comparable results obtained from completely randomized predictions about which 
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participants had a LRRK2 mutation or were iPD (these predictions are akin to outcomes of 
an unbiased coin flip and are based on chance alone). Moreover, the differences in LRRK2-
PD and iPD voice recordings is also evident from the scatterplot of salient features that 
shows two distinct clusters, as presented in Supplementary Figure 4. 
Detecting and characterising identity confounding 
Digital recordings of voice and other sensor data from individuals can capture properties of 
these data which are unique to particular individuals, in the following way. For example, in 
voice, the combination of various vocal features such as vocal pitch and spectral envelope 
may occupy an approximately unique region in feature space, distinct from all other 
individuals in the study. This uniqueness can interact with highly nonlinear classifiers to 
produce ‘identity confounding’ whereby the classifier finds a relationship between the 
individual and their specific clinical grouping, rather than a relationship between clinical 
symptoms and clinical grouping. This inadvertent relationship can confound predictions, 
which means that it is necessary to quantify the extent to which the classifier is making 
predictions which would generalize to individuals not in the study. To quantify this potential 
confound, we counted the number of observations and individuals per unique predicted 
value in the classification tree (across 500 trees used); whereby each tree was built using a 
bootstrap sample of the training data. Averaged over all cross-validation repetitions (10-fold 
with 100 repetitions), we found that the average number of observations per unique 
predicted value and corresponding number of participants were 8.2 and 4.5, respectively, 
for LRRK2-PD versus iPD. The average number of participants in the training set (after 
balancing the data and bootstrapping) in each tree for the above pairwise comparison was 
10.9. While training the model, the unique predicted values thus had observations from 
around 41% of the individuals that were in the training set (4.5 individuals on average), thus 
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indicating that this form of identity confounding is unlikely to be a significant factor in the 
results presented in this study. 
Prodromal versus Nonprodromal  
We investigated if two non-manifesting carriers classified as being in the prodromal state 
were more similar to their non-prodromal counterparts compared to participants with 
LRRK2-PD. One of the two participants meeting prodromal criteria was more similar to the 
manifesting LRRK2 carriers on the basis of the two most salient voice features, 
(Supplementary Figure 3). However, the sample size was too small to draw any reliable 
inferences.  
 
LRRK2 carriers vs idiopathic PD 
For the LRRK2 carrier group, we analyzed 50 recordings, collected from 27 individuals (mean 
age: 61.9 years (SD 15.3); % female: 48.2%; mean UPDRSIII: 8.7 (SD 12.4)), whereas for the 
iPD group, we analyzed 32 recordings, collected from 17 individuals (mean age: 63.4 years 
(SD 8.7); % female: 53.0%; mean UPDRSIII: 22.8 (SD 10.0)). Age for the LRRK2 carrier and iPD 
groups were similar at 5% significance level (unpaired t-test). As expected, UPDRS III for the 
LRRK2 carrier group was significantly lower compared to the iPD group (Mann–Whitney U 
test). In distinguishing LRRK2 carriers and iPD, using the 10 most salient features, the mean 
sensitivity was 74.8% (SD 26.5%) and mean specificity was 83.0% (SD 22.3%). We used 10-
fold CV with 100 repetitions. The differences in the features for LRRK2-carriers versus iPD 
were thus less pronounced, compared to the case when features for LRRK2-PD were 
compared against iPD. Further investigations are using larger cohorts are needed to 
investigate if non-manifesting and manifesting LRRK2 carriers can be treated as belonging to 
the same clinical group. 
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SUPPLEMENTARY TABLE 1: Brief description of five categories of features extracted from the voice 
recordings. 
 
Category   Brief description 
Category 1: Descriptive features: 
 
Mean, median, standard 
deviation, skewness, 
interquartile range etc. 
Quantifies statistical characteristics of the voice signal 
Category 2: Vocal fold vibration-based features: 
 
Jitter  
 
Quantifies the instabilities of the oscillating pattern of the vocal 
folds by measuring cycle-to-cycle changes in the fundamental 
frequency (measure of roughness in voice) 
Shimmer Quantifies the instabilities of the oscillating pattern of the vocal 
folds by measuring cycle-to-cycle changes in the amplitude 
(measure of roughness in voice) 
Teager-Kaiser Energy 
Operator (TKEO) 
Measures the instantaneous changes in voice energy (takes into 
account both amplitude and frequency) 
Category 3: Cepstral coefficients based features: 
 
Mel Frequency Cepstral 
Coefficients  (MFCCs) 
Computes the contribution of the energy of the speech signal at 
each frequency band (are aimed at detecting subtle changes in the 
motion of the articulators) 
Category 4: Aeroacoustics, aperiodicity, and frequency based features: 
Recurrence Period Density 
Entropy (RPDE) 
Quantifies any ambiguity in fundamental pitch (RPDE is zero for 
perfectly periodic signals and one for purely stochastic signals). 
Higher RPDE has been associated with voice impairment 
Detrended Fluctuation 
Analysis (DFA) 
Characterizes the changing detail of aero-acoustic breath noise  
Pitch Period Entropy (PPE) Measures the impaired control of stable pitch, a property common 
in PD 
Harmonics-to-Noise Ratio 
(HNR) 
Quantifies noise in the speech signal, caused mainly due to 
incomplete vocal fold closure 
Glottal to Noise Excitation 
(GNE) ratio 
Quantifies the extent of noise in speech using linear and nonlinear 
energy measures 
Vocal Fold Excitation Ratios 
(VFER) 
Quantifies the extent of noise in speech using energy (linear and 
nonlinear) and entropy-based measures  
Perturbation Quotient (PQ) Quantifies variations in speech signal 
Glottis Quotient (GQ) Quantifies properties of the vocal folds (when glottis is open and 
closed)  
F0 contour features Measures based the summary statistics of the fundamental 
frequency 
Category 5: Wavelet-based features: 
 
Wavelet related measures Variants of above-discussed summary measures applied to wavelet 
coefficients of the speech signal 
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SUPPLEMENTARY TABLE 2.  Discrimination accuracy for the leave-one-subject-out (LOSO) cross-
validation (CV) scheme for the three pairwise comparisons: LRRK2-associated Parkinson’s disease 
(LRRK2-PD) versus idiopathic PD (iPD), non-manifesting LRRK2 mutation carriers (NMC) versus related 
non-carriers (RNC), and NMC versus healthy controls, computed using a machine learning algorithm 
(random forest) and a naïve benchmark (randomized predictions). 
 
 
Discrimination accuracy 
 
Sensitivity (%) 
Mean (SD) 
 
Specificity (%) 
Mean (SD) 
LRRK2-PD vs iPD (ALL)   
Random forest 83.7% (7.1%) 88.5% (8.4%) 
Randomized predictions 51.6% (20.2%) 47.0% (18.3%) 
   
NMC vs RNC (ALL)   
Random forest 67.3% (3.2%) 69.8% (4.9%) 
Randomized predictions 48.6% (13.1%) 47.3% (11.1%) 
   
NMC vs Healthy (ALL)   
Random forest 72.4% (3.2%) 69.9% (5.0%) 
Randomized predictions 50.4% (10.0%) 48.9% (11.6%) 
 
 
 
The above sensitivity and specificity values were computed separately for each of the three priority pairwise comparisons 
(1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs Healthy) using a leave-one-subject-out (LOSO) cross-validation (CV) 
scheme, employing 10 most salient voice features. Validation scheme involved repetitive splitting of the data such that at a 
given CV iteration, all voice tests from only one randomly selected participant were employed for model validation, while 
voice tests from all remaining participants were used for training. We used LOSO CV scheme with 100 repetitions. The data 
was balanced to account for differences in number of participants in each clinical group. Accuracies are reported for a 
machine learning classifier (random forest) and a naïve benchmark based on randomized predictions (expected accuracy 
around 50%), using all available voice tests from the five clinical groups (1. LRRK2-PD, 2. iPD, 3. NMC, 4. RNC, and, 5. 
Healthy controls). The sensitivity and specificity values were presented in percentage (%) as mean (and standard deviation, 
in brackets), whereby the standard deviation denotes the variability in the accuracy across multiple CV repetitions. The 
rankings of the most salient features were obtained separately for each of the three pairwise comparisons, using a majority 
voting scheme (using 5 feature selection algorithms). Abbreviations used: iPD, idiopathic Parkinson’s disease; LRRK2-PD, 
LRRK2-associated Parkinson’s disease; NMC, non-manifesting carriers; RNC, related non-carriers; SD, standard deviation. 
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SUPPLEMENTARY TABLE 3: List of 10 salient features selected for the three pairwise comparisons. 
 
Feature Name        Brief description 
Comparison 1: LRRK2-associated PD vs iPD 
Skewness 
det_entropy_log_6_coef 
 
GNE-SEO 
Quantifies asymmetry of the distribution 
Wavelet log-entropy of the 6th detail coefficient of F0, 
quantifies subtle changes in the details of F0 fluctuations 
Glottal to Noise Excitation Squared Energy Operator, 
quantifies excessive noise and turbulence in the voice 
VFER-LF-TKEO  
 
 
prctile50TKEO_A0 
app_det_TKEO_mean_4_coef 
Vocal Fold Excitation Ratio, quantifies incomplete vocal fold 
closure which creates vortices and inconsistencies across 
frequency bands in terms of energy  
Median of the Teager-Kaiser Energy of amplitude 
Mean Teager-Kaiser Energy of the 4th wavelet decomposiition 
coefficient decomposing F0, quantifies subtle changes in the 
energy of F0 
medMFCC3 
 
app_entropy_log_8_coef 
 
det_entropy_shannon_6_coef 
 
Median value of the 3rd MFCC coefficient, quantifies 
envelope structure fluctuations 
Entropy of the 8th approximation wavelet decomposition 
coefficient, quantifies changes in F0 
Shannon entropy of the 6th detail wavelet decomposition 
coefficient, quantifies changes in F0 
Q1 25th quartile 
Comparison 2: Non-manifesting carriers (NMC) versus related controls 
det_LT_TKEO_mean_4_coef  
 
HNR(1) 
 
Mean(A0) 
medShimmer 
PQ11.class_Schoentgen 
Mean Teager-Kaiser Energy of the 4th detail wavelet 
decomposition coefficient, quantifies changes in F0 
Harmonics to Noise Ratio, quantifies signal to noise, i.e. the 
extent of vocal noise using standard autocorrelation 
Mean amplitude 
Quantifies amplitude perturbations 
Amplitude perturbation using a 11-sample window 
muDiffMFCC5 
medMFCC10 
 
medJitter 
mode_F0 
det_LT_TKEO_mean_8_coef 
5th MFCC 
Median of 10th MFCC, quantifies mostly higher harmonic 
components in the signal 
Quantifies frequency perturbations 
Dominating F0 value 
Mean Teager-Kaiser Energy of the 8th detail wavelet 
decomposition coefficient 
Comparison 3: Non-manifesting carriers (NMC) versus unrelated controls 
muDiffMFCC13 
muDiffMFCC8 
medShimmer 
13th MFCC  
Quantifies mostly higher harmonic components in the signal 
Quantifies amplitude perturbations 
Ed2_8_coef 
PQ11.class_Schoentgen 
Wavelet energy of the 8th wavelet coefficient 
Amplitude perturbation using a 11-sample window 
medMFCC10 
Ed2_7_coef 
det_entropy_log_6_coef 
 
Quantifies mostly higher harmonic components in the signal 
Wavelet energy of the 7th wavelet coefficient 
Wavelet log energy the 6th detail wavelet decomposition 
coefficient, quantifies changes in F0 
P0 Perturbation quotient (zeroth order) 
HNR(1) Harmonics to Noise Ratio, quantifies signal to noise, i.e. the extent 
of vocal noise using standard autocorrelation 
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SUPPLEMENTARY FIGURE 1. Scatterplots and boxplots of salient features for the pairwise comparison: 
LRRK2-associated Parkinson’s disease (LRRK2-PD) versus idiopathic PD (iPD). 
 
 
 
Panel A plots two salient features, Skewness (amplitude) and Vocal Fold Excitation Ratio (VFER, the degree of signal 
strength over noise resulting from incomplete vocal fold closure), both skewness and VFER were significantly different 
between the two groups, (p<0.001, denoted by ***) (Panel B). Panel C plots mean Teager Kaiser Energy Operator (TKEO, 
quantifies instantaneous changes in voice energy) and a Wavelet coefficient (based on TKEO), while Panel D shows that 
these features were significantly different between LRRK2-PD and iPD. Panel E plots the Mel Frequency Cepstral 
Coefficients (MFCC, quantifies vocal fold dynamics taking into account the properties of the articulators) and Entropy 
(entropy computed after wavelet decomposition, computes the extent of randomness in a signal), while Panel F shows that 
these features were statistically significantly different (p<0.01). Features with high discriminatory power were identified 
using five different feature selection algorithms. The above plots were generated using all voice recordings collected from 
participants with LRRK2-PD and iPD. p values reported above were computed using the nonparametric two-sided 
Kolmogorov-Smirnov (KS) test. 
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SUPPLEMENTARY FIGURE 2. Discrimination accuracies as a function of the number of salient features 
used in the machine learning discrimination analysis, for the three pairwise comparisons: LRRK2-
associated Parkinson’s disease (LRRK2-PD) versus idiopathic PD (iPD) (Panels A and B), non-
manifesting LRRK2 mutation carriers (NMC) versus related non-carriers (RNC) (Panels C and D), and 
NMC versus healthy controls (Panels E and F). 
 
 
The above accuracies were computed using all available voice recordings from the five clinical groups (1. LRRK2-PD, 2. iPD, 
3. NMC, 4. RNC, and, 5. Healthy controls), using 10-fold cross-validation (100 repetitions). The rankings of the most salient 
features were obtained using a majority voting scheme (using 5 feature selection algorithms). The feature rankings were 
obtained separately for each of the above 3 pairwise comparisons (1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs 
Healthy). Features were added into the machine learning classifier (random forest) in increments of 2 (starting from 2, and 
going up to 30), whereby higher ranked features were added first. The whole process of training and validation was 
repeated each time two new features were included. Mean sensitivity and specificity values are denoted as grey circles and 
reported in percentage (%). 
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SUPPLEMENTARY FIGURE 3. Scatterplot of two most salient features that help discriminate LRRK2-
associated Parkinson’s disease (LRRK2-PD) versus non-manifesting LRRK2 mutation carriers (NMC), 
plotted along with features from prodromal participants. 
 
 
 
The feature rankings were obtained separately for the above pairwise comparison: LRRK2-PD versus NMC. We analysed 
three voice recordings from two prodromal participants (denoted as a grey square). 
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SUPPLEMENTARY FIGURE 4. Scatterplot of two most salient features that help discriminate LRRK2-
associated Parkinson’s disease (LRRK2-PD) versus idiopathic PD (iPD), plotted along with voice 
features from the excluded LRRK2-PD participant. 
 
 
 
We analysed 10 voice recordings collected from six LRRK2-PD participants (denoted as grey crosses) and 32 voice 
recordings obtained from seventeen iPD participants (denoted as light grey circles). Analysis excluded one LRRK2-PD 
participant who had disease duration of 36 years, note that we only had one decent quality voice recording for this 
participant (denoted as a dark grey circle).  
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